SCHEMBL23959588

SCHEMBL23959588

CCOC(=O)c1nn(CC(=O)OC(C)(C)C)c2c1C1C(C)C1C2

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.33
CYP2C19 P33261 2/20 0.33
CYP2C9 P11712 1/20 0.33
TRPM2 O94759 1/20 0.32
KMT2A Q03164 1/20 0.32
ADORA1 P30542 2/20 0.31
ADORA3 P0DMS8 1/20 0.31
ADORA2A P29274 1/20 0.31
CCNA2 P20248 1/20 0.31
CDK2 P24941 1/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
ALDH1A1 P00352 2/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
ENPP2 Q13822 1/20 0.30
TSHR P16473 2/20 0.30
MAPK1 P28482 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2D6 P10635 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23959619 1.00 STAT3 (0.33) STAT3CYP2C19CYP2C9TRPM2KMT2A
SCHEMBL23959581 0.86 ALDH1A1 (0.36) KMT2ACCNA2CDK2NPC1RAB9A
SCHEMBL24878671 0.81 IDO1 (0.36) STAT3CYP2C19CYP2C9TRPM2KMT2A
SCHEMBL24878539 0.81 IDO1 (0.36) STAT3CYP2C19CYP2C9TRPM2KMT2A
SCHEMBL21995752 0.76 TRPM2 (0.33) STAT3TRPM2KMT2AADORA1NPC1
SCHEMBL22054063 0.75 ADORA1 (0.33) KMT2AADORA1ALDH1A1SMN1; SMN2TSHR
SCHEMBL21752547 0.75 TRPM2 (0.45) STAT3CYP2C19TRPM2ALDH1A1SMN1; SMN2
SCHEMBL16006803 0.75 TRPM2 (0.47) STAT3CYP2C19TRPM2KMT2AALDH1A1
SCHEMBL14487962 0.75 MEN1 (0.34) CYP2C19CYP2C9KMT2ANPC1RAB9A
SCHEMBL21995948 0.74 TRPM2 (0.36) STAT3CYP2C19CYP2C9TRPM2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210330676-A1 NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210330676-A1 NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS IDO1, IDO2, KYNU STAT3 4395/4885CYP2C19 435/4885CYP2C9 606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.